Adam J. Causer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adam J. Causer has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Zoe Louise Saynor
University Hospital Southampton NHS Foundation Trust Southampton UK
10 shared publications - Anthony Ian Shepherd
Clinical, Health and Rehabilitation Research Team, School of Psychology, Sport and Health Science, Faculty of Science and Health University of Portsmouth Portsmouth UK
9 shared publications - Janis Kay Shute
School of Pharmacy and Biomedical Sciences University of Portsmouth Portsmouth UK
7 shared publications Gary Connett
National Institute for Health Research Southampton Biomedical Research Centre Southampton Children’s Hospital Southampton UK
6 shared publicationsMark I. Allenby
Wessex Cystic Fibrosis Unit University Hospital Southampton Foundation NHS Trust Southampton UK
6 shared publicationsMary P. Carroll
Wessex Cystic Fibrosis Unit University Hospital Southampton Foundation NHS Trust Southampton UK
6 shared publications
Latest Publications
- Open Access
- 1 December 2021
- Published by Wiley in Physiological Reports
- Vol. 9 (23) , e15128
CFTR limits F‐actin formation and promotes morphological alignment with flow in human lung microvascular endothelial cells
Cystic fibrosis transmembrane conductance regulator (CFTR) in human lung microvascular endothelial cells (HLMVEC) appears to limit cytosolic actin polymerization while maintaining a cortical rim fila...
- 1 December 2021
- Published by Wiley in Physiological Reports
- Vol. 9 (23) , e15128
Open AccessCFTR limits F‐actin formation and promotes morphological alignment with flow in human lung microvascular endothelial cells
Cystic fibrosis transmembrane conductance regulator (CFTR) in human lung microvascular endothelial cells (HLMVEC) appears to limit cytosolic actin polymerization while maintaining a cortical rim fila...
- 1 May 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (3) , 485-488
Heat acclimation improves sweat gland function and lowers sweat sodium concentration in an adult with cystic fibrosis
- 1 May 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (3) , 485-488
Heat acclimation improves sweat gland function and lowers sweat sodium concentration in an adult with cystic fibrosis
- 28 April 2021
- Published by Wiley in Journal of Human Nutrition and Dietetics
- Vol. 35 (2) , 363-375
The impact of plasma 25‐hydroxyvitamin D on pulmonary function and exercise physiology in cystic fibrosis: A multicentre retrospective study
Background: A 25‐hydroxyvitamin D (25OHD) may exert immunomodulatory effects on respiratory health, which may translate to improvements in exercise physiology. Thus, we aimed to investigate whether plasma 25OHD is associated with lung function and aerobic fitness in people with cystic fibrosis (pwCF).Methods: A multicentre retrospective review of pwCF (> 9 years old) attending the Royal Hospital for Sick Children (Edinburgh) or Wessex CF‐Unit (Southampton) was performed between July 2017 and October 2019. Demographic and clinical data were collected. Plasma 25OHD measured closest in time to clinical cardiopulmonary exercise testing and/or spirometry [forced expiratory volume (FEV1)% predicted] was recorded. Pancreatic insufficiency was diagnosed based on faecal elastase of < 100 µg g−1. We performed multiple‐regression analysis with aerobic fitness outcomes [peak oxygen uptake (VO2 peak)] and FEV1% predicted as primary outcomes.Results: Ninety pwCF [mean ± SD age: 19.1 ± 8.6 years, 54 (60%) children, 48 (53%) males and 88 (98%) Caucasian] were included. 25OHD deficiency and insufficiency was 15 (17%) and 44 (49%), respectively. 25OHD deficiency and insufficiency was significantly associated with pancreatic insufficiency (χ2 = 4.8, p = 0.02). Plasma 25OHD was not significantly associated with FEV1% predicted (r2 = 0.06, p = 0.42, 95% CI = −0.09 to 0.19) or VO2 peak (r2 = 0.04, p = 0.07, 95% CI = −011 to 0.005) in all pwCF. However, 25OHD was significantly associated with both FEV1% (r2 = 0.15, p = 0.02, 95% CI = 1.99–2.64) and VO2 peak (r2 = 0.13, p = 0.05, 95% CI = −0.26 to −0.005) in the paediatric cohort.Conclusions: We showed that 25OHD is associated with improved lung function and aerobic fitness in children and adolescents with CF. Mechanistic and high‐quality prospective studies including both lung function and aerobic fitness as primary outcomes are now warranted.
- 28 April 2021
- Published by Wiley in Journal of Human Nutrition and Dietetics
- Vol. 35 (2) , 363-375
The impact of plasma 25‐hydroxyvitamin D on pulmonary function and exercise physiology in cystic fibrosis: A multicentre retrospective study
Background: A 25‐hydroxyvitamin D (25OHD) may exert immunomodulatory effects on respiratory health, which may translate to improvements in exercise physiology. Thus, we aimed to investigate whether plasma 25OHD is associated with lung function and aerobic fitness in people with cystic fibrosis (pwCF).Methods: A multicentre retrospective review of pwCF (> 9 years old) attending the Royal Hospital for Sick Children (Edinburgh) or Wessex CF‐Unit (Southampton) was performed between July 2017 and October 2019. Demographic and clinical data were collected. Plasma 25OHD measured closest in time to clinical cardiopulmonary exercise testing and/or spirometry [forced expiratory volume (FEV1)% predicted] was recorded. Pancreatic insufficiency was diagnosed based on faecal elastase of < 100 µg g−1. We performed multiple‐regression analysis with aerobic fitness outcomes [peak oxygen uptake (VO2 peak)] and FEV1% predicted as primary outcomes.Results: Ninety pwCF [mean ± SD age: 19.1 ± 8.6 years, 54 (60%) children, 48 (53%) males and 88 (98%) Caucasian] were included. 25OHD deficiency and insufficiency was 15 (17%) and 44 (49%), respectively. 25OHD deficiency and insufficiency was significantly associated with pancreatic insufficiency (χ2 = 4.8, p = 0.02). Plasma 25OHD was not significantly associated with FEV1% predicted (r2 = 0.06, p = 0.42, 95% CI = −0.09 to 0.19) or VO2 peak (r2 = 0.04, p = 0.07, 95% CI = −011 to 0.005) in all pwCF. However, 25OHD was significantly associated with both FEV1% (r2 = 0.15, p = 0.02, 95% CI = 1.99–2.64) and VO2 peak (r2 = 0.13, p = 0.05, 95% CI = −0.26 to −0.005) in the paediatric cohort.Conclusions: We showed that 25OHD is associated with improved lung function and aerobic fitness in children and adolescents with CF. Mechanistic and high‐quality prospective studies including both lung function and aerobic fitness as primary outcomes are now warranted.
- Open Access
- 29 July 2020
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 11, 879
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Human Lung Microvascular Endothelial Cells Controls Oxidative Stress, Reactive Oxygen-Mediated Cell Signaling and Inflammatory Responses
Background; Perturbation of endothelial function in people with cystic fibrosis (CF) has been reported, which may be associated with endothelial cell expression of the cystic fibrosis transmembrane conductance regulator (CFTR). Previous reports indicate that CFTR activity upregulates endothelial barrier function, endothelial nitric oxide synthase (eNOS) expression and NO release, while limiting interleukin-8 (IL-8) release, in human umbilical vein endothelial cells (HUVECs) in cell culture. In view of reported microvascular dysfunction in people with CF we investigated the role of CFTR expression and activity in the regulation of oxidative stress, cell signalling and inflammation in human lung microvascular endothelial cells (HLMVECs) in cell culture. Methods; HLMVECs were cultured in the absence and presence of the CFTR inhibitor GlyH-101 and CFTR siRNA. CFTR expression was analysed using qRT-PCR, immunocytochemistry (IHC) and western blot, and function by membrane potential assay. IL-8 expression was analysed using qRT-PCR and ELISA. Nrf2 expression, and NF-κB and AP-1 activation were determined using IHC and western blot. The role of the epidermal growth factor receptor (EGFR) in CFTR signalling was investigated using the EGFR tyrosine kinase inhibitor AG1478. Oxidative stress was measured as intracellular ROS and hydrogen peroxide concentration. VEGF and SOD-2 were measured in culture supernatants by ELISA. Results; HLMVECs express low levels of CFTR that increase following inhibition of CFTR activity. Inhibition of CFTR, significantly increased intracellular ROS and hydrogen peroxide levels over 30 minutes and significantly decreased Nrf2 expression by 70% while increasing SOD-2 expression over 24h. CFTR siRNA significantly increased constitutive expression of IL-8 by HLMVECs. CFTR inhibition activated the AP-1 pathway and increased IL-8 expression, without effect on NF-κB activity. Conversely, TNF-α activated the NF-κB pathway and increased IL-8 expression. The effects of TNF-α and GlyH-101 on IL-8 expression were additive and inhibited by AG1478. Inhibition of both CFTR and EGFR in HLMVECs significantly increased VEGF expression. The antioxidant N-acetyl cysteine significantly reduced ROS production and the increase in IL-8 and VEGF expression following CFTR inhibition. Conclusions; Functional endothelial CFTR limits oxidative stress and contributes to the normal anti-inflammatory state of HLMVECs. Therapeutic strategies to restore endothelial CFTR function in CF are warranted.
- 29 July 2020
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 11, 879
Open AccessCystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Human Lung Microvascular Endothelial Cells Controls Oxidative Stress, Reactive Oxygen-Mediated Cell Signaling and Inflammatory Responses
Background; Perturbation of endothelial function in people with cystic fibrosis (CF) has been reported, which may be associated with endothelial cell expression of the cystic fibrosis transmembrane conductance regulator (CFTR). Previous reports indicate that CFTR activity upregulates endothelial barrier function, endothelial nitric oxide synthase (eNOS) expression and NO release, while limiting interleukin-8 (IL-8) release, in human umbilical vein endothelial cells (HUVECs) in cell culture. In view of reported microvascular dysfunction in people with CF we investigated the role of CFTR expression and activity in the regulation of oxidative stress, cell signalling and inflammation in human lung microvascular endothelial cells (HLMVECs) in cell culture. Methods; HLMVECs were cultured in the absence and presence of the CFTR inhibitor GlyH-101 and CFTR siRNA. CFTR expression was analysed using qRT-PCR, immunocytochemistry (IHC) and western blot, and function by membrane potential assay. IL-8 expression was analysed using qRT-PCR and ELISA. Nrf2 expression, and NF-κB and AP-1 activation were determined using IHC and western blot. The role of the epidermal growth factor receptor (EGFR) in CFTR signalling was investigated using the EGFR tyrosine kinase inhibitor AG1478. Oxidative stress was measured as intracellular ROS and hydrogen peroxide concentration. VEGF and SOD-2 were measured in culture supernatants by ELISA. Results; HLMVECs express low levels of CFTR that increase following inhibition of CFTR activity. Inhibition of CFTR, significantly increased intracellular ROS and hydrogen peroxide levels over 30 minutes and significantly decreased Nrf2 expression by 70% while increasing SOD-2 expression over 24h. CFTR siRNA significantly increased constitutive expression of IL-8 by HLMVECs. CFTR inhibition activated the AP-1 pathway and increased IL-8 expression, without effect on NF-κB activity. Conversely, TNF-α activated the NF-κB pathway and increased IL-8 expression. The effects of TNF-α and GlyH-101 on IL-8 expression were additive and inhibited by AG1478. Inhibition of both CFTR and EGFR in HLMVECs significantly increased VEGF expression. The antioxidant N-acetyl cysteine significantly reduced ROS production and the increase in IL-8 and VEGF expression following CFTR inhibition. Conclusions; Functional endothelial CFTR limits oxidative stress and contributes to the normal anti-inflammatory state of HLMVECs. Therapeutic strategies to restore endothelial CFTR function in CF are warranted.
- 1 May 2020
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 19 (3) , 427-433
The implications of dysglycaemia on aerobic exercise and ventilatory function in cystic fibrosis
- 1 May 2020
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 19 (3) , 427-433
The implications of dysglycaemia on aerobic exercise and ventilatory function in cystic fibrosis
- Open Access
- 23 January 2020
- Published by Elsevier in Redox Biology
- Vol. 32, 101436
Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis
- 23 January 2020
- Published by Elsevier in Redox Biology
- Vol. 32, 101436
Open AccessCirculating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis
- 1 February 2019
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 126 (2) , 512
Reply to Askew and Green
- 1 February 2019
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 126 (2) , 512
Reply to Askew and Green
- 1 January 2019
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 126 (1) , 265
Reply to Cooper
- 1 January 2019
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 126 (1) , 265
Reply to Cooper
- 1 October 2018
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 125 (4) , 1277-1283
Cardiopulmonary exercise testing with supramaximal verification produces a safe and valid assessment of V̇o2max in people with cystic fibrosis: a retrospective analysis
The validity and safety of using supramaximal verification (Smax) to confirm a maximal effort during cardiopulmonary exercise testing (CPET) in people with cystic fibrosis (CF) and/or those with severe disease has been questioned. Therefore, this study aimed to investigate these concerns in children, adolescents, and adults with mild-to-severe CF lung disease. Retrospective analysis of 17 pediatric and 28 adult participants with CF [age range: 9.2–62.9 y; forced expiratory volume in 1 s: 66.7% (range: 29.9%–102.3%); 30 men] who completed a routine ramp-incremental cycling test to determine peak oxygen uptake (V̇o2peak) was studied. Maximal oxygen uptake (V̇o2max) was subsequently confirmed by Smax at 110% of peak power output. All participants satisfied the criteria to verify a maximal effort during CPET. However, Smax-V̇o2peak exceeded ramp-V̇o2peak in 3/14 (21.4%) of pediatric and 6/28 (21.4%) adult exercise tests. A valid measurement of V̇o2max was attained in 85.7% of pediatric and 96.4% of adult exercise tests, as Smax-V̇o2peak did not exceed ramp-V̇o2peak by >9%. Adults ( n = 9) experienced a ≥5% reduction in arterial O2 saturation during CPET, 4 during both the ramp and Smax, 3 during only the ramp, and 2 during only Smax. Smax did not significantly worsen perceived breathing effort, chest tightness, throat narrowing, or exertion compared with ramp-incremental testing. Given the clinical importance of aerobic fitness in people with CF, incorporating Smax is recommended to provide a safe and valid measure of V̇o2max in children, adolescents, and adults who span the spectrum of CF disease severity. NEW & NOTEWORTHY Incorporating supramaximal verification into cardiopulmonary exercise testing protocols did not increase the frequency of adverse events or perceived discomfort versus a single-phase incremental exercise test in people with mild-to-severe cystic fibrosis. Furthermore, a valid measure of maximal oxygen uptake (V̇o2max) was obtained from 85.7% of pediatric and 96.4% of adult exercise tests, whereas peak oxygen uptake underestimated aerobic fitness in comparison with V̇o2max in 21.4% of cases (by up to 24.4%).
- 1 October 2018
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 125 (4) , 1277-1283
Cardiopulmonary exercise testing with supramaximal verification produces a safe and valid assessment of V̇o2max in people with cystic fibrosis: a retrospective analysis
The validity and safety of using supramaximal verification (Smax) to confirm a maximal effort during cardiopulmonary exercise testing (CPET) in people with cystic fibrosis (CF) and/or those with severe disease has been questioned. Therefore, this study aimed to investigate these concerns in children, adolescents, and adults with mild-to-severe CF lung disease. Retrospective analysis of 17 pediatric and 28 adult participants with CF [age range: 9.2–62.9 y; forced expiratory volume in 1 s: 66.7% (range: 29.9%–102.3%); 30 men] who completed a routine ramp-incremental cycling test to determine peak oxygen uptake (V̇o2peak) was studied. Maximal oxygen uptake (V̇o2max) was subsequently confirmed by Smax at 110% of peak power output. All participants satisfied the criteria to verify a maximal effort during CPET. However, Smax-V̇o2peak exceeded ramp-V̇o2peak in 3/14 (21.4%) of pediatric and 6/28 (21.4%) adult exercise tests. A valid measurement of V̇o2max was attained in 85.7% of pediatric and 96.4% of adult exercise tests, as Smax-V̇o2peak did not exceed ramp-V̇o2peak by >9%. Adults ( n = 9) experienced a ≥5% reduction in arterial O2 saturation during CPET, 4 during both the ramp and Smax, 3 during only the ramp, and 2 during only Smax. Smax did not significantly worsen perceived breathing effort, chest tightness, throat narrowing, or exertion compared with ramp-incremental testing. Given the clinical importance of aerobic fitness in people with CF, incorporating Smax is recommended to provide a safe and valid measure of V̇o2max in children, adolescents, and adults who span the spectrum of CF disease severity. NEW & NOTEWORTHY Incorporating supramaximal verification into cardiopulmonary exercise testing protocols did not increase the frequency of adverse events or perceived discomfort versus a single-phase incremental exercise test in people with mild-to-severe cystic fibrosis. Furthermore, a valid measure of maximal oxygen uptake (V̇o2max) was obtained from 85.7% of pediatric and 96.4% of adult exercise tests, whereas peak oxygen uptake underestimated aerobic fitness in comparison with V̇o2max in 21.4% of cases (by up to 24.4%).